The regulation, known as Regulation 18(1)(b) concerns applications that might not be supported by the Pharmaceutical Needs Assessment (PNA) but would still confer significant benefits on the local population. It requires the health service commissioning board to consider whether granting the application would offer substantial advantages to people in the area which was not anticipated when the PNA was published.

Source: The Times May 24, 2025 14:39 UTC